Identification of Candidate Risk Factor Genes for Human Idelalisib Toxicity Using a Collaborative Cross Approach

Idelalisib is a phosphatidylinositol 3-kinase inhibitor highly selective for the delta isoform that has shown good efficacy in treating chronic lymphocytic leukemia and follicular lymphoma. In clinical trials, however, idelalisib was associated with rare, but potentially serious liver and lung toxic...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Toxicol Sci
Päätekijät: Mosedale, Merrie, Cai, Yanwei, Eaddy, John Scott, Corty, Robert W, Nautiyal, Manisha, Watkins, Paul B, Valdar, William
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2019
Aiheet:
Clinical and Translational Toxicology
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6876541/
https://ncbi.nlm.nih.gov/pubmed/31501888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/toxsci/kfz199
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia